We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+12.15%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.85B
AUM Growth
+$519M
Cap. Flow
+$404M
Cap. Flow %
21.87%
Top 10 Hldgs %
27.4%
Holding
120
New
9
Increased
56
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$54.3M
2
CYBR
CyberArk
CYBR
+$36.5M
3
ABBV icon
AbbVie
ABBV
+$26.6M
4
QLIK
QLIK TECHNOLOGIES INC COM STK (DE)
QLIK
+$18.5M
5
IMPV
Imperva, Inc.
IMPV
+$18.2M

Top Sells

Rank Stock Value
1
SNDK
SANDISK CORP
SNDK
+$20.5M
2
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$11.8M
3
CXP
COLUMBIA PROPERTY TRUST, INC.
CXP
+$10.6M
4
VMW
VMware, Inc
VMW
+$8.02M
5
OII icon
Oceaneering
OII
+$7M

Sector Composition

Rank Sector Weight
1 Healthcare 28.49%
2 Technology 26.09%
3 Consumer Discretionary 12.82%
4 Industrials 9.62%
5 Energy 3.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
76
DELISTED
Dynavax Technologies
DVAX
$4.56M 0.25%
194,500
+67,100
+53% +$1.46M
CERN
77
DELISTED
Cerner Corp
CERN
$4.51M 0.24%
65,300
+5,200
+9% +$364K
TGTX icon
78
TG Therapeutics
TGTX
$8.19B
$4.5M 0.24%
271,100
+88,100
+48% +$1.4M
CSLT
79
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$4.48M 0.24%
+550,600
New +$4.59M
GWPH
80
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.43M 0.24%
36,100
+2,600
+8% +$295K
LOXO
81
DELISTED
Loxo Oncology, Inc
LOXO
$4.39M 0.24%
243,700
+129,100
+113% +$1.76M
RGEN icon
82
Repligen
RGEN
$8.1B
$4.1M 0.22%
99,400
– –
DRNA
83
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.84M 0.21%
275,300
+133,200
+94% +$2.44M
DBVT
84
DBV Technologies
DBVT
$817M
$3.82M 0.21%
12,840
+3,200
+33% +$827K
AZPN
85
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$3.78M 0.2%
83,000
– –
ATRC icon
86
AtriCure
ATRC
$2.04B
$3.75M 0.2%
152,300
– –
NTUS
87
DELISTED
Natus Medical Inc
NTUS
$3.19M 0.17%
75,000
– –
ESPR
88
DELISTED
Esperion Therapeutics
ESPR
$3.19M 0.17%
39,000
– –
AGTC
89
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.15M 0.17%
205,500
– –
SAGE
90
DELISTED
Sage Therapeutics
SAGE
$2.94M 0.16%
40,200
– –
XLRN
91
DELISTED
Acceleron Pharma
XLRN
$2.76M 0.15%
87,100
– –
CSII
92
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.74M 0.15%
103,700
+17,700
+21% +$572K
ARAY icon
93
Accuray
ARAY
$34M
$2.46M 0.13%
364,600
– –
QURE icon
94
uniQure
QURE
$2.93B
$2.44M 0.13%
90,500
– –
ONCE
95
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.3M 0.12%
+38,200
New +$2.53M
INSM icon
96
Insmed
INSM
$22B
$2.16M 0.12%
88,600
– –
IMDZ
97
DELISTED
Immune Design Corp.
IMDZ
$2.13M 0.12%
102,904
+20,947
+26% +$495K
OMED
98
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1.92M 0.1%
85,100
– –
ATHN
99
DELISTED
Athenahealth, Inc.
ATHN
$1.87M 0.1%
16,300
– –
RGLS
100
DELISTED
Regulus Therapeutics
RGLS
$1.76M 0.1%
1,338
+371
+38% +$599K
1 2 3
4
5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Eventide Asset Management held 120 positions worth $1.85B, up 39% from $1.33B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management deployed $404M of net new capital in Q2 2015, opening 9 new positions and adding to 56 existing holdings. Its largest new stake was CyberArk: 570,000 shares worth $35.8M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was inContact, Inc., an estimated $443K trimmed.

  • Eventide Asset Management's largest Q2 2015 buy was CyberArk: 570,000 shares worth $35.8M.
  • Eventide Asset Management added most to Celgene Corp in Q2 2015, an estimated $54.3M increase.
  • Eventide Asset Management's biggest Q2 2015 reduction was inContact, Inc., cutting an estimated $443K.
  • Eventide Asset Management fully exited SANDISK CORP in Q2 2015, selling an estimated $20.5M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $1.85B portfolio in Q2 2015.
  • Eventide Asset Management opened 9 new positions and closed 10 in Q2 2015.
  • Eventide Asset Management's portfolio value rose 39% quarter-over-quarter to $1.85B.

Based on Eventide Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.